Phreesia, Inc. (NYSE:PHR – Get Free Report) General Counsel Allison C. Hoffman sold 4,585 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $26.90, for a total transaction of $123,336.50. Following the transaction, the general counsel now directly owns 154,552 shares of the company’s stock, valued at approximately $4,157,448.80. This trade represents a 2.88 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Phreesia Price Performance
Shares of PHR opened at $27.24 on Monday. The firm has a market capitalization of $1.58 billion, a price-to-earnings ratio of -18.53 and a beta of 0.94. The firm’s fifty day simple moving average is $23.54 and its 200-day simple moving average is $22.83. Phreesia, Inc. has a twelve month low of $17.07 and a twelve month high of $29.16. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04.
Phreesia (NYSE:PHR – Get Free Report) last announced its quarterly earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The company had revenue of $106.80 million during the quarter, compared to the consensus estimate of $106.33 million. During the same period in the previous year, the business earned ($0.58) EPS. Phreesia’s revenue for the quarter was up 16.6% on a year-over-year basis. Equities analysts forecast that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.
Hedge Funds Weigh In On Phreesia
Analysts Set New Price Targets
PHR has been the subject of several research reports. Truist Financial lifted their target price on shares of Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Citigroup boosted their price objective on Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a report on Friday, January 10th. JMP Securities restated a “market outperform” rating and set a $30.00 target price on shares of Phreesia in a report on Tuesday, December 10th. Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and boosted their price target for the stock from $24.00 to $32.00 in a research note on Wednesday, January 8th. Finally, Needham & Company LLC reissued a “buy” rating and set a $29.00 price target on shares of Phreesia in a research report on Friday, January 10th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Phreesia has an average rating of “Buy” and a consensus price target of $31.00.
View Our Latest Research Report on PHR
Phreesia Company Profile
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Featured Articles
- Five stocks we like better than Phreesia
- What Makes a Stock a Good Dividend Stock?
- Earn High Dividends With 2 Top REITs Set to Perform in 2025
- Expert Stock Trading Psychology Tips
- Oilfield Leader SLB: An AI Name You Need to Know
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Top ETFs That Beat the Market in 2024 and Could Do It Again
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.